The Food and Drug Administration has approved Belimumab, an anti-BAFF antibody, as a treatment for SLE due to its efficacy in reducing disease activity and re-occurrences, called flares, in patients with active SLE [17]. This evidence concerns the gene TNFSF13B and systemic lupus erythematosus.